ReviewCancer prevention research (Philadelphia, Pa.)2010
Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans.
Review in Cancer prevention research (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.Cancer prevention research (Philadelphia, Pa.) · 2012Trial
- Putrescine-bound structure and multi-temperature crystallography provide new insights into ligand binding and conformational heterogeneity in spermidine synthase.Structural dynamics (Melville, N.Y.) · 2026Article
- Structure simulation-based comparison of active site variations in fungal ornithine decarboxylases.Communicative & integrative biology · 2025Article
- Microbial Metabolite Dysbiosis and Colorectal Cancer.Gut and liver · 2023Review
- An update on clinical trials for chemoprevention of human skin cancer.Journal of cancer metastasis and treatment · 2023Article
- Cyano-Phycocyanin: Mechanisms of Action on Human Skin and Future Perspectives in Medicine.Plants (Basel, Switzerland) · 2022Review
- Genetic regulation of spermine oxidase activity and cancer risk: a Mendelian randomization study.Scientific reports · 2021Article
- The First Insight Into the Supramolecular System ofFrontiers in chemistry · 2021Article
- Polyamines and related signaling pathways in cancer.Cancer cell international · 2020Review
- Polyamine Metabolism as a Therapeutic Target inHedgehog-Driven Basal Cell Carcinomaand Medulloblastoma.Cells · 2019Review
- Skin Carcinogenesis Studies Using Mouse Models with Altered Polyamines.Cancer growth and metastasis · 2015Review
- Polyamine depletion inhibits the autophagic response modulating Trypanosoma cruzi infectivity.Autophagy · 2013Article
- Polyamines and cancer: implications for chemotherapy and chemoprevention.Expert reviews in molecular medicine · 2013Review
- Article
- Pathogenesis of nonmelanoma skin cancers in organ transplant recipients.Archives of biochemistry and biophysics · 2011Review
- Deciphering squamous cell carcinoma using multidimensional genomic approaches.Journal of skin cancer · 2011Article
- Cytoplasmic accumulation of the RNA-binding protein HuR stabilizes the ornithine decarboxylase transcript in a murine nonmelanoma skin cancer model.The Journal of biological chemistry · 2010Article
- Novel investigational drugs for basal cell carcinoma.Expert opinion on investigational drugs · 2010Review
- Nonsurgical innovations in the treatment of nonmelanoma skin cancer.The Journal of clinical and aesthetic dermatology · 2010Article
- Untargeted Metabolomics of Breast Cancer Cells MCF-7 and SkBr3 Treated With Tamoxifen/Trastuzumab.Cancer genomics & proteomicsArticle
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bailey et al. report in this issue of the journal (beginning on page 35) one of the first successful trials of basal cell carcinoma (BCC) prevention. Oral alpha-difluoromethyl-dl-ornithine (DFMO) reduced new BCCs in patients with a prior history of nonmelanoma skin cancer. DFMO is an inhibitor of ornithine decarboxylase, a key enzyme in the polyamine biosynthetic pathway. This perspective on Bailey et al. discusses our knowledge of the contribution of polyamines to BCC pathogenesis, how this knowledge advanced the development of a new method to prevent BCCs, and prospects for future studies of DFMO in BCC prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.